脐血干细胞移植治疗慢性肝衰竭患者的临床观察

发布时间：2018-03-02 22:23

本文选题：慢性肝衰竭　切入点：脐血干细胞移植　出处：《实用医学杂志》2017年04期 　论文类型：期刊论文

【摘要】：目的:观察脐血干细胞移植治疗慢性肝衰竭患者的安全性及临床疗效。方法:慢性肝衰竭患者44例,其中对照组22例,给予内科综合治疗,治疗组22例,在内科综合治疗的基础上给予脐血干细胞治疗。观察治疗前和治疗后2、4、12、24周生化指标、MELD评分、临床症状、生存情况及不良反应。结果:治疗组白蛋白、凝血酶原活动度较对照组升高,MELD评分较对照组降低,生存率较对照组升高,组间比较有统计学差异(P0.05);两组丙氨酸转氨酶、总胆红素比较无统计学差异(P0.05)。治疗4周后,治疗组乏力、食欲、腹胀及腹水情况均较对照组改善,差异有统计学意义(P0.05)。两组患者均未出现明显不良反应,无肝细胞癌发生。结论:脐血干细胞移植治疗慢性肝衰竭患者安全有效,可明显提高患者生存率。
[Abstract]:Objective: to observe the safety and clinical efficacy of umbilical cord blood stem cell transplantation in the treatment of chronic liver failure. On the basis of comprehensive medical treatment, umbilical cord blood stem cells were treated. The 24 week biochemical index meld, clinical symptoms, survival status and adverse reactions were observed before and after treatment. Results: albumin was used in the treatment group. The prothrombin activity was higher than that in the control group and meld score was lower than that in the control group, and the survival rate was higher than that in the control group. There was a significant difference between the two groups (P 0.05), but there was no significant difference in the ratio of alanine aminotransferase and total bilirubin between the two groups (P 0.05). The condition of fatigue, appetite, abdominal distension and ascites in the treatment group was improved compared with the control group, and the difference was statistically significant (P 0.05). Conclusion: umbilical cord blood stem cell transplantation is safe and effective in the treatment of patients with chronic liver failure.
【作者单位】：河北医科大学第一医院中西医结合肝病诊疗中心;
【基金】：河北省医学科学研究重点课题(编号:20150636)
【分类号】：R575.3

【相似文献】